Taconic Biosciences Expands Immuno-oncology Animal Model PortfolioCritical Jh Syngeneic Tumor Model Host Now Available on a B6 Background
The Pharma Data
JANUARY 17, 2021
a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio. . Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. RENSSELAER, N.Y.,
Let's personalize your content